Abortion Research Today is a free monthly online journal that collates and summarizes the latest research about Abortion, including details on abortion pill, procedure, facts, information.

Intravaginal gemeprost and second-trimester pregnancy termination in the scarred uterus.

Marinoni E, Santoro M, Vitagliano MP, Patella A, Cosmi EV, Di Iorio R

Laboratory of Perinatal Medicine and Molecular Biology, Department of Gynecology, Perinatology and Child Health, University La Sapienza, Rome, Italy. emanuelamarinoni@hotmail.com <emanuelamarinoni@hotmail.com>

OBJECTIVE: To investigate the effectiveness and complication rate of intravaginal gemeprost, a prostaglandin E(1) analogue, for second-trimester pregnancy termination in women with a scarred uterus. METHODS: Of 439 women undergoing induced abortion between the 13th and the 23rd week of pregnancy, 67 had a scarred uterus because of 1 or more cesarean sections or myomectomy. All women received a 1 mg dose of gemeprost intravaginally every 3 h, up to 5 times over 24 h. Those who did not respond received further cycles of gemeprost treatment. RESULTS: The rate of successful abortions among women with uterine scars was not different from that observed in the nulliparous controls, but previously vaginal delivery was associated with a shorter induction to abortion interval. The rate of severe complications did not differ between the groups, and was about 1%. CONCLUSION: The rate of complications following intravaginal administration of a PGE(1) analogue for second-trimester pregnancy termination was similar in women with a scarred or unscarred uterus.

Published 12 March 2007 in Int J Gynaecol Obstet, 97(1): 35-9.
Full-text of this article is available online (may require subscription).

© 2004-2008 Abortion Research Today. All Rights Reserved.